The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
Open accessAbstract
Key Points: High CRM1 expression was associated with short survival of AML patients. CRM1 inhibitor KPT-185 induces apoptosis mainly in a p53-dependent manner, whereas inhibition of proliferation was p53 independent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“OCI-AML-3, MOLM-13, and MV4;11 have wild-type p53; whereas NB4, HL-60, KG-1, THP-1, and U937 have defective (deleted or missense mutated) p53.(7,25) Cell lines were harvested in log-phase growth, seeded at a density of 2 3 10(5) cells per mL and exposed to compounds.”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Cited by
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationGenomic and molecular characterization of esophageal squamous cell carcinoma
Lin, D.-C., Hao, J.-J., Nagata, Y., Xu, L., Shang, L., Meng, X., Sato, Y., Okuno, Y., Varela, A. M., Ding, L.-W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2935 · Cited by 626
Self-citationResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
Self-citation
Metadata
- Authors
- Kojima, K., Kornblau, S. M., Ruvolo, V., Dilip, A., Duvvuri, S., Davis, R. E., Zhang, M., Wang, Z., Coombes, K. R., Zhang, N., Qiu, Y. H., Burks, J. K., Kantarjian, H., Shacham, S., Kauffman, M., & Andreeff, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-05-16
- Volume
- 121
- Issue
- 20
- Pages
- 4166-4174
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2009386327
- Cited by
- 206
- References
- 5
- FWCI
- 13.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic impact and targeting of CRM1 in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2012-08-447581
- The paper
- Kojima, K., Kornblau, S. M., Ruvolo, V., Dilip, A., Duvvuri, S., Davis, R. E., Zhang, M., Wang, Z., Coombes, K. R., Zhang, N., Qiu, Y. H., Burks, J. K., Kantarjian, H., Shacham, S., Kauffman, M., & Andreeff, M. (2013). Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2012-08-447581
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.